Valerio Therapeutics Société anonyme (EPA:ALVIO)

Market Cap	93.90M +838.2%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	499.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164,825
Open	0.1900
Previous Close	0.1880
Day's Range	0.1860 - 0.1942
52-Week Range	0.0422 - 0.3100
Beta	1.81
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 25
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVIO

Financial Performance

In 2025, EPA:ALVIO's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.